Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded up 3.3% on Wednesday . The stock traded as high as $372.44 and last traded at $371.57, with a volume of 1,063,121 shares traded. The stock had previously closed at $359.61.

Several analysts have weighed in on the stock. Leerink Swann reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, March 19th. Piper Jaffray Cos. reissued a “hold” rating and issued a $443.00 price target on shares of Regeneron Pharmaceuticals in a research note on Saturday, April 2nd. Robert W. Baird reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, April 2nd. Roth Capital reissued a “buy” rating and issued a $520.00 price target (down from $555.00) on shares of Regeneron Pharmaceuticals in a research note on Saturday, April 2nd. Finally, Cowen and Company reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Sunday, April 17th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $508.69.

The firm’s 50-day moving average is $373.88 and its 200-day moving average is $405.81. The company has a market capitalization of $38.75 billion and a P/E ratio of 58.91.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $2.57 earnings per share for the quarter, missing analysts’ consensus estimates of $2.58 by $0.01. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter in the prior year, the firm posted $2.88 earnings per share. The company’s quarterly revenue was up 38.0% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals Inc. will post $10.89 EPS for the current fiscal year.

In other news, EVP Plew Daniel P. Van sold 4,413 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were sold at an average price of $385.77, for a total transaction of $1,702,403.01. Following the transaction, the executive vice president now directly owns 11,381 shares in the company, valued at $4,390,448.37. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sanofi bought 64,731 shares of the stock in a transaction dated Tuesday, June 14th. The shares were acquired at an average price of $363.86 per share, for a total transaction of $23,553,021.66. The disclosure for this purchase can be found here.

Several institutional investors have made changes to their positions in REGN. Financial Counselors Inc. raised its position in shares of Regeneron Pharmaceuticals by 5.3% in the fourth quarter. Financial Counselors Inc. now owns 1,846 shares of the biopharmaceutical company’s stock worth $1,002,000 after buying an additional 93 shares during the period. Brown Advisory Inc. raised its position in shares of Regeneron Pharmaceuticals by 3.1% in the fourth quarter. Brown Advisory Inc. now owns 1,920 shares of the biopharmaceutical company’s stock worth $1,042,000 after buying an additional 58 shares during the period. Victory Capital Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 106.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,072 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 1,067 shares during the period. Stephens Inc. AR raised its position in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Stephens Inc. AR now owns 2,488 shares of the biopharmaceutical company’s stock worth $1,351,000 after buying an additional 190 shares during the period. Finally, Private Advisor Group LLC raised its position in shares of Regeneron Pharmaceuticals by 17.4% in the fourth quarter. Private Advisor Group LLC now owns 2,506 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 371 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.